ADC Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
10 Maio 2023 - 8:15AM
Business Wire
ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet
Mallik, Chief Executive Officer, will participate in a fireside
chat at the RBC Capital Markets Global Healthcare Conference in New
York City on Tuesday, May 16th at 10:00 a.m. EDT.
A live webcast of the presentation will be available via the
Events & Presentations page in the Investors section of ADC
Therapeutics’ website, ir.adctherapeutics.com. A replay of the
webcast will be available for approximately 30 days.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global
leader and pioneer in the field of antibody drug conjugates (ADCs).
The Company is advancing its proprietary ADC technology to
transform the treatment paradigm for patients with hematologic
malignancies and solid tumors.
ADC Therapeutics’ CD19-directed ADC ZYNLONTA (loncastuximab
tesirine-lpyl) received accelerated approval by the FDA and
conditional approval from the European Commission for the treatment
of relapsed or refractory diffuse large B-cell lymphoma after two
or more lines of systemic therapy. ZYNLONTA is also in development
in combination with other agents and in earlier lines of therapy.
In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in
ongoing clinical and preclinical development.
ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and
has operations in London, the San Francisco Bay Area and New
Jersey. For more information, please visit
https://adctherapeutics.com/ and follow the Company on Twitter and
LinkedIn.
ZYNLONTA® is a registered trademark of ADC Therapeutics SA.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements are
subject to certain risks and uncertainties that can cause actual
results to differ materially from those described. Factors that may
cause such differences include, but are not limited to: the success
of the Company’s updated corporate strategy including operating
efficiencies, capital deployment and portfolio prioritization; the
Company’s ability to achieve the 2023 net product sales guidance
for ZYNLONTA® and the decrease in total operating expenses for 2023
and 2024, the expected cash runway into the middle of 2025, the
effectiveness of the new commercial go-to-market strategy and the
Company’s ability to continue to commercialize ZYNLONTA® in the
United States and future revenue from the same; Swedish Orphan
Biovitrum AB (Sobi®) ability to successfully commercialize
ZYNLONTA® in the European Economic Area and market acceptance,
adequate reimbursement coverage, and future revenue from the same;
our strategic partners’, including Mitsubishi Tanabe Pharma
Corporation and Overland Pharmaceuticals, ability to obtain
regulatory approval for ZYNLONTA® in foreign jurisdictions, and the
timing and amount of future revenue and payments to us from such
partnerships; the Company’s ability to market its products in
compliance with applicable laws and regulations; the Company’s
expectations regarding the impact of the Infrastructure Investment
and Jobs Act; the timing and results of the Company’s or its
partners’ research projects or clinical trials including LOTIS 5, 7
and 9, ADCT 901, 601 and 602, the timing and outcome of regulatory
submissions and actions by the FDA or other regulatory agencies
with respect to the Company’s products or product candidates;
projected revenue and expenses; the Company’s indebtedness,
including Healthcare Royalty Management and Blue Owl and Oaktree
facilities, and the restrictions imposed on the Company’s
activities by such indebtedness, the ability to repay such
indebtedness and the significant cash required to service such
indebtedness; the Company’s ability to obtain financial and other
resources for its research, development, clinical, and commercial
activities and other statements regarding matters that are not
historical facts, and involve predictions. These statements involve
known and unknown risks, uncertainties and other factors that may
cause actual results, performance, achievements or prospects to be
materially different from any future results, performance,
achievements or prospects expressed in or implied by such
forward-looking statements. In some cases you can identify
forward-looking statements by terminology such as “may”, “will”,
“should”, “would”, “expect”, “intend”, “plan”, “anticipate”,
“believe”, “estimate”, “predict”, “potential”, “seem”, “seek”,
“future”, “continue”, or “appear” or the negative of these terms or
similar expressions, although not all forward-looking statements
contain these identifying words. Additional information concerning
these and other factors that may cause actual results to differ
materially from those anticipated in the forward-looking statements
is contained in the “Risk Factors” section of the Company's Annual
Report on Form 20-F and in the Company's other periodic reports and
filings with the Securities and Exchange Commission. The Company
cautions investors not to place undue reliance on the
forward-looking statements contained in this document. The Company
undertakes no obligation to revise or update these forward-looking
statements to reflect events or circumstances after the date of
this press release, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230510005088/en/
Investors Eugenia Litz ADC Therapeutics
Eugenia.Litz@adctherapeutics.com +44 7879 627205
Amanda Loshbaugh ADC Therapeutics
Amanda.Loshbaugh@adctherapeutics.com +1 917-288-7023
Media Mary Ann Ondish ADC Therapeutics
Maryann.Ondish@adctherapeutics.com +1 914-552-4625
ADC Therapeutics (NYSE:ADCT)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
ADC Therapeutics (NYSE:ADCT)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024